For adolescents aged 12 to 17 years, reactions to homologous Pfizer-BioNTech booster vaccination occur with similar frequency as after receipt of the second vaccine dose, and they are generally mild to moderate in severity, according to research published in the March 1 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Homologous Pfizer-BioNTech booster safe for adolescents
For adolescents aged 12 to 17 years, reactions to homologous Pfizer-BioNTech booster vaccination occur with similar frequency as after receipt of the second vaccine dose, and they are generally mild to moderate in severity, according to research published in the March 1 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.